Table 1 Baseline characteristics of all 1013 patients with ischemic stroke, and of those with (n = 72) or without CIAD (n = 941), respectively
All stroke patients n = 1013 | Stroke patients without CIAD n = 941 | Stroke patients with CIAD n = 72 | p* | |
|---|---|---|---|---|
Age; median (IQR) | 69.0 (61.0–78.0) | 69.0 (60.0–78.0) | 73.0 (65.3–78.8) | 0.042 |
Female sex; % (n) | 46.8 (474) | 47.0 (442) | 44.4 (32) | 0.679 |
Comorbidities; % (n) | ||||
Previous stroke or TIA | 24.0 (243) | 24.0 (226) | 23.6 (17) | 0.938 |
Atrial fibrillation | 26.5 (268) | 26.0 (245) | 31.9 (23) | 0.273 |
Diabetes | 28.0 (284) | 27.5 (259) | 34.7 (25) | 0.190 |
Hypertension | 71.8 (727) | 71.6 (674) | 73.6 (53) | 0.718 |
Coronary artery disease | 21.6 (219) | 21.0 (198) | 29.2 (21) | 0.106 |
Peripheral artery disease | 6.0 (61) | 5.7 (54) | 9.7 (7) | 0.171 |
Chronic heart failure | 16.6 (168) | 16.5 (155) | 18.1 (13) | 0.728 |
Mechanical heart valve | 0.4 (4) | 0.4 (4) | 0.0 (0) | 0.579 |
NIHSS† score; % (n) | 0.169 | |||
0 – 10 points | 75.9 (769) | 76.3 (718) | 70.8 (51) | |
≥ 11 points | 24.1 (244) | 23.7 (223) | 29.2 (21) | |
Modified Rankin Scale score; % (n) | 0.080 | |||
0–1 | 16.9 (171) | 17.4 (164) | 9.7 (7) | |
2–3 | 47.5 (481) | 47.5 (447) | 47.2 (34) | |
4–5 | 35.6 (361) | 35.1 (330) | 43.1 (31) | |
Antithrombotic medication prior to admission; % (n) | 0.370 | |||
None | 66.4 (672) | 65.9 (619) | 73.6 (53) | |
Antiplatelets | 28.8 (291) | 29.5 (277) | 19.4 (14) | |
Vitamin K antagonist | 4.0 (40) | 3.7 (35) | 6.9 (5) | |
Vitamin K antagonist & antiplatelet | 0.3 (3) | 0.3 (3) | 0.0 (0) | |
Heparin, full-dose | 0.5 (5) | 0.5 (5) | 0.0 (0) | |
Heparin, full-dose & antiplatelet | 0.1 (1) | 0.1 (1) | 0.0 (0) | |
Thrombolysis with rt-PA; % (n) | 7.8 (79) | 7.7 (72) | 9.7 (7) | 0.351 |
In-hospital mortality; % (n) | 3.7 (37) | 3.6 (34) | 4.2 (0) | 0.742 |